Exploring DVAI for your organisation? Arrange a confidential, no-obligation discussion. Confidential discussion
Pharma Agents · Cluster 3 of 5

Pharmacovigilance & genomics

Post-market safety and sensitive data — structuring adverse-event intake for safety officers, and orchestrating genomic pipelines locally so multi-gigabyte datasets stay within their jurisdiction of origin.

Use case 505

Genomic data pipeline orchestration

The pain point

A single human genome generates roughly 100–200 gigabytes of raw data.57 The bottleneck is rarely sequencing itself but orchestrating secondary analysis — alignment, variant calling — across hybrid, localised networks where data-residency rules apply and multi-gigabyte datasets cannot freely cross borders.

Impact — organisation

Compute idle time and orchestration overhead; the tension between analysis throughput and strict data-residency obligations; sensitive genomic data at risk if moved.

Impact — customer / client

For patients, slower personalised-medicine profiles; and a real privacy stake in where their genomic data lives.

How it’s addressed

Running on Bridge’s local inference fabric, the agent automates pipeline-orchestration steps and validation logging while keeping multi-gigabyte genomic datasets inside their country of origin. It handles file-system routing and validation logs — it does not diagnose genetic anomalies or alter data sequences.

The benefits
Organisation

Designed to reduce orchestration idle time while keeping genomic data within its jurisdiction of origin — sovereignty and throughput together, rather than a trade-off.

Customer / client

For patients, faster personalised-medicine profiles with their genomic data kept in-country.

Use case 507

Pharmacovigilance adverse-event intake triage

The pain point

Post-market surveillance brings a heavy inflow of potential Adverse Event reports across phone, web and email. Manually reading, logging and categorising them strains safety teams and raises the risk of missing a critical MHRA/FDA reporting window.

GxP regulatory boundary. Within a GxP environment the MHRA/FDA boundary is absolute: this agent does not create, alter, delete or approve any regulated GxP record, and it gives no clinical or medical advice. It triages, summarises and surfaces information for the review and validated signature of a qualified human (21 CFR Part 11 / EudraLex Annex 11). Every regulated decision, and the integrity of every record, remains with the responsible person.
Impact — organisation

Safety teams overloaded by manual AE intake; the regulatory and patient-safety risk of a missed reporting deadline; inconsistent initial data capture.

Impact — customer / client

For patients, the risk that a genuine safety signal is delayed in the queue.

How it’s addressed

The agent captures raw verbal or written AE reports and structures them into standard formats (such as E2B) for the safety team. It performs administrative intake only — it makes no seriousness or causality determination, passing every structured dossier to a qualified Safety Officer for evaluation.

The benefits
Organisation

Designed to speed and standardise the administrative intake of adverse-event reports so safety officers reach the evaluation faster — the clinical judgement of seriousness and causality remaining entirely human.

Customer / client

For patients, a lower chance that a genuine safety signal is lost or delayed in administrative backlog.

Previous cluster Manufacturing & quality (GxP)

See how these map onto your organisation. Request a confidential discussion.

Get started
Confidential discussion

Talk to our Customer Success Team.

Take it further with a confidential, no-obligation discussion to scope a pilot in your environment.

Private & no-obligation

Every enquiry is held in confidence. We’ll walk you through the use cases relevant to you and scope how a sovereign deployment would work in your environment — with no obligation to proceed.

Request a meeting with the CST

We aim to respond within one working day.

Held in confidence · no obligation

Sources & references

Statistics describe demand and conditions across the relevant sector and are drawn from the cited public sources. They characterise the sector-level problem these agents address; they are not performance claims for any DVAI product. Deep Voice AI Limited is a pre-revenue company and makes no representation as to outcomes for any individual organisation. Figures are current as at the date of the cited publications.

Capable AI, on your terms — not the cloud’s.

Products
Business Agents
Company
Legal